Ibrutinib and venetoclax in combination for chronic lymphocytic leukemia: synergy in practice

The combination of ibrutinib and venetoclax has emerged as a promising therapeutic strategy for patients with chronic lymphocytic leukemia (CLL). Preclinical investigations demonstrated a synergistic antitumor effect through multiple mechanisms, providing a robust foundation for translating this regimen into clinical trials. Beyond the dual inhibition by 2 small molecules, another innovative concept being tested with this combination is the use of measurable residual disease (MRD)-driven treatment versus fixed-duration treatment, meeting the escalating demand for oral, convenient, cost-effective, and time-limited therapeutic approaches. The clinical translation of this combination has yielded remarkable outcomes, with significant improvement of progression-free survival (PFS) and overall survival (OS) rates for both treatment-naïve and relapsed/refractory CLL. Notably, a substantial proportion of patients achieved undetectable MRD (uMRD). Clinical trial updates following initial published results have shown consistency and durability of responses over time. This review synthesizes the initial investigator-initiated trial results for ibrutinib and venetoclax, examines several multicenter clinical trial designs and outcomes, addresses variables such as chromosome 17p deletion that influence treatment responses and discuss the safety of the regimen. Additionally, we review the usage of this combination in other B-cell malignancies and discuss how current knowledge can be utilized for shaping future CLL treatment regimens.